B-hPD-1 Mice Plus

Basic Information

Strain Name
C57BL/6-Pdcd1tm3(PDCD1)Bcgen/Bcgen
Stock Number
110019
Common Name
B-hPD-1 mice Mice plus
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
Pd-1 (Programmed death-1)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Description

PD-1 (Programmed death-1) is mainly expressed on the surface of T cells and primary B cells. The two PD-1 ligands, PD-L1 and PD-L2, are widely expressed on antigen-presenting cells (APCs). PD-1 interacts with its ligands and plays an important role in the negative regulation of the immune response. PD-L1 protein expression is detected in many human tumor tissues. PD-L1 expression in tumor cells could be induced by the microenvironment of tumor cells. PD-L1 expression is favorable for tumorigenesis and growth, for induction of anti-tumor T Cell apoptosis, and for tumor escape from immune system. Inhibition of PD- 1 binding to its ligand can result in tumor cells that are exposed to the killing version of the immune system, and thus is a target for cancer treatments.

Targeting Strategy

Details

Phenotype

Protein Expression Analysis

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1 mice (plus) were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1 mice (plus).

 

 

Application

Human PD-1 antibody (Opdivo) Efficacy Evaluation

B-hPD-1-mice-Mice-Plus-details-pd-1-opdivo-efficacy-evaluation

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1 mice plus. Mice were grouped when the tumor size was 150±50 mm3 (n=6). The human PD-1 antibody Opdivo significantly inhibited tumor growth, confirming that the B-hPD-1 plus mouse model is a powerful tool for in vivo PD-1 antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

Human PD-1 antibody (Keytruda) Efficacy Evaluation

B-hPD-1-mice-Mice-Plus-details-pd-1-keytruda-efficacy-evaluation

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1 mice plus. Mice were grouped when the tumor size was 150±50 mm3 (n=6). The human PD-1 antibody Keytruda significantly inhibited tumor growth, confirming that the B-hPD-1 plus mouse model is a powerful tool for in vivo PD-1 antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

1. Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369.
2. EMBO J. 1992 Nov;11(11):3887-95.
3. J Exp Med. 2000 Oct 2;192(7):1027-34.
4. Science. 2001 Jan 12;291(5502):319-22.

Back to top